DAA’s in the treatment of HCV: The Beginning of the end or the end of the

beginning for HCV?

HCV-Related Cirrhosis Is Projected to Peak Over the Next 10 Years

Sustained Virologic Response Improves Overall Survival in Chronic HCV with Advanced Fibrosis

DAAs as Components of New Treatment Paradigm for Hepatitis C

Eric the Sailor

The story continues

Interferon has a Dual Mechanism of Action: Viral Inhibition and Immune Modulation

The addition of RBV Significantly Accelerates Viral Decay

Pharmacokinetics of Once Daily Compared with Twice Daily Regimen of Ribavirin

Eric’s HCV Treatment course

Definitions of Response

DAAs - Key Characteristics

Protease Inhibitor DAAs in Clinical Trials

5 Non Nucleoside Polymerase Inhibitors

4 Nucleoside Analogue Polymerase Inhibitors

4 NS5A Inhibitors

3 Other Classes

Eric Update

Eric comes ashore

Rash Decisions

Progress on study

Eric Week 24 to 48 and 72

Newly Approved HCV Agents: Telaprevir and Boceprevir

Treatment Naïve HCV G1

Sprint 2 Boceprevir Naïve

Sprint 2 SVR and Relapse Rates

SPRINT-2 and RESPOND-2: HCV G1 Subtype as a Predictor of SVR in Patients with Poor IFN Response (BOC Arms Combined)

Patients With Poor Interferon Response and Fail Treatment Are More Likely to Have RAVs

Changes in HCV RNA over Time During Previous Phase I Studies (101/103)

C219: HCV RNA Values over Time (Week 8 Interim Analysis, TVR-exposed)

MK 5172 Second Generation PI

Advance: SVR and Relapse Rates

Previously Treated Patients HCV G1

Respond-2

Respond-2

REALIZE: Insulin resistance was not an independent determinant of SVR

REALIZE: Impact of anemia/RBV dose reduction on SVR

PILLAR Study:TMC 435SVR24 (ITT)

Silen C 1 Virologic response BI 1335

Atlas Efficacy: Achievement of HCV RNA <15 IU/mL

PSI-7977 ELECTRON: Study Design for HCV GT2/3

PSI-7977 ELECTRON100% concordance of SVR12 with SVR24

PSI-7977 ELECTRONWhat is the role of Ribavirin?

BI 201335 and BI 207127, with and without ribavirin, in treatment-naïve patients with chronic genotype-1 HCV infection: Week 12

interim results of the SOUND-C2 study

SVR-12

Background

BMS-790052 (NS5A inhibitor) + BMS-650032 (PI) ± PR in null responders: phase IIa study

Virologic Response before and after treatment

Dual therapy with BMS 790052 + BMS 650032 in HCV genotype 1B null responsders

The Holy Grail